Latest News

The loss of physical function seen in aging tissues is partly due to the formation of irreversible crosslinks between proteins. A new paper in ACS Chemical Biology reports SRF-funded work in the lab of Yale’s Prof. David Spiegel on an antibody that specifically labels the major crosslink glucosepane – a crucial step towards its removal.

The removal of damaged material from within atherosclerotic plaques (“fatty streaks”) to restore cardiovascular health is a key component of SENS, now being developed for the clinic by SRF ally Underdog Pharmaceuticals. Exciting new preclinical results from another group using this strategy have recently been published in ACS Nano.

Dr. Jonathan Clark’s SRF-funded group at the Babraham Institute have published two new papers showing that the current model in which aging tissues lose elasticity due to the accumulation of stable crosslinks is not the full story – results which will be crucial to reversing that deterioration.

2020 has already seen six new SRF-supported papers – including validation of a key tactic to prevent mitochondrial aging by our MitoSENS team, and an in-depth review coauthored by SRF, Underdog Pharmaceuticals and professor W. Gray Jerome on the major LysoSENS target 7-ketocholesterol.

A team including SRF protégé Stuart Calimport and several members of our Research Advisory Board argues in Science that the systematic classification and staging of aging-related pathology (as is currently done for cancer) should dramatically accelerate the deployment of rejuvenation therapies.